Development of Self-Microemulsifying Drug Delivery System to Improve Nisoldipine Bioavailability : Cell Line and In Vivo Evaluations : Development of Self-Microemulsifying Drug Delivery System
© 2021. American Association of Pharmaceutical Scientists..
The authors attempted to fabricate a novel lipid-based formulation of a lipophilic drug, nisoldipine (NISO). As NISO belongs to BCS class 2 drug, it suffers from low bioavailability (5%). Hence, the research was intended to ameliorate oral bioavailability of NISO via intestinal lymphatic transport. The NISO loaded self microemulsifying drug delivery system (SMEDDS) (NISO SMEDDS) was prepared using Peceol, Cremophor EL, and Transcutol HP. The Cremophor EL and Transcutol HP at 1:1 ratio showed maximum microemulsifying area, and average globule size was 16.78 ± 0.97 nm with PDI 0.121 ± 0.024. Cellular uptake studies (confocal microscopy and flow cytometry) using Caco-2 cells depicted higher fluorescence with coumarin-6 loaded SMEDDS as that of coumarin-6 solution which indicated deeper penetration. Mean fluorescence intensity (MFI) of coumarin-6 loaded SMEDDS was significantly improved (9.92-fold) in contrast to coumarin-6 solution. The NISO SMEDDS showed enhanced permeability (5.02 times) across Caco-2 cells compared to NISO suspension. The bioavailability improvement with NISO SMEEDS was 2.14 times relative to suspension, and lymphatic uptake was involved in oral absorption of NISO SMEDDS.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
AAPS PharmSciTech - 22(2021), 8 vom: 21. Okt., Seite 256 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mundada, Veenu P [VerfasserIn] |
---|
Links: |
---|
Themen: |
4I8HAB65SZ |
---|
Anmerkungen: |
Date Completed 25.11.2021 Date Revised 25.11.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1208/s12249-021-02109-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM332166120 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM332166120 | ||
003 | DE-627 | ||
005 | 20231225215033.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1208/s12249-021-02109-4 |2 doi | |
028 | 5 | 2 | |a pubmed24n1107.xml |
035 | |a (DE-627)NLM332166120 | ||
035 | |a (NLM)34676456 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mundada, Veenu P |e verfasserin |4 aut | |
245 | 1 | 0 | |a Development of Self-Microemulsifying Drug Delivery System to Improve Nisoldipine Bioavailability |b Cell Line and In Vivo Evaluations : Development of Self-Microemulsifying Drug Delivery System |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.11.2021 | ||
500 | |a Date Revised 25.11.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. American Association of Pharmaceutical Scientists. | ||
520 | |a The authors attempted to fabricate a novel lipid-based formulation of a lipophilic drug, nisoldipine (NISO). As NISO belongs to BCS class 2 drug, it suffers from low bioavailability (5%). Hence, the research was intended to ameliorate oral bioavailability of NISO via intestinal lymphatic transport. The NISO loaded self microemulsifying drug delivery system (SMEDDS) (NISO SMEDDS) was prepared using Peceol, Cremophor EL, and Transcutol HP. The Cremophor EL and Transcutol HP at 1:1 ratio showed maximum microemulsifying area, and average globule size was 16.78 ± 0.97 nm with PDI 0.121 ± 0.024. Cellular uptake studies (confocal microscopy and flow cytometry) using Caco-2 cells depicted higher fluorescence with coumarin-6 loaded SMEDDS as that of coumarin-6 solution which indicated deeper penetration. Mean fluorescence intensity (MFI) of coumarin-6 loaded SMEDDS was significantly improved (9.92-fold) in contrast to coumarin-6 solution. The NISO SMEDDS showed enhanced permeability (5.02 times) across Caco-2 cells compared to NISO suspension. The bioavailability improvement with NISO SMEEDS was 2.14 times relative to suspension, and lymphatic uptake was involved in oral absorption of NISO SMEDDS | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Caco-2 cell line | |
650 | 4 | |a bioavailability | |
650 | 4 | |a lymphatic uptake | |
650 | 4 | |a nisoldipine | |
650 | 4 | |a self-microemulsifying drug delivery system | |
650 | 7 | |a Emulsions |2 NLM | |
650 | 7 | |a Nisoldipine |2 NLM | |
650 | 7 | |a 4I8HAB65SZ |2 NLM | |
700 | 1 | |a Patel, Mitali H |e verfasserin |4 aut | |
700 | 1 | |a Mundada, Piyush K |e verfasserin |4 aut | |
700 | 1 | |a Sawant, Krutika K |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d 2000 |g 22(2021), 8 vom: 21. Okt., Seite 256 |w (DE-627)NLM126699429 |x 1530-9932 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2021 |g number:8 |g day:21 |g month:10 |g pages:256 |
856 | 4 | 0 | |u http://dx.doi.org/10.1208/s12249-021-02109-4 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2021 |e 8 |b 21 |c 10 |h 256 |